A phase 1b trial of duvelisib, a PI3K-δ,γ inhibitor, in combination with obinutuzumab in patients with CLL/SLL previously treated with a Bruton’s tyrosine kinase inhibitor (BTKi)

Authors :: Jill Rodstrom
Jennifer R. Brown
John C. Byrd
Nitin Jain
James S. Blachly
Jacqueline C. Barrientos
Virginia Kelly
Shijie Tang
Jennifer Sweeney
Stephanie Garnick
Source :: Journal of Clinical Oncology. 33:TPS7100-TPS7100
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: TPS7100 Background: Abrogating B-cell receptor pathway signaling through BTK inhibition is an effective treatment strategy for CLL. However, some patients (pts) do not respond, or progress despite ...

Tools